RFG Advisory LLC Invests $234,000 in Qiagen (NYSE:QGEN)

RFG Advisory LLC purchased a new stake in Qiagen (NYSE:QGEN) during the fourth quarter, according to its most recent filing with the SEC. The firm purchased 5,266 shares of the company’s stock, valued at approximately $234,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wellington Management Group LLP raised its holdings in Qiagen by 77.7% in the third quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company’s stock worth $963,386,000 after purchasing an additional 9,293,040 shares during the period. Barclays PLC raised its stake in Qiagen by 170.6% during the 3rd quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock worth $84,259,000 after buying an additional 1,165,594 shares during the period. Victory Capital Management Inc. lifted its holdings in Qiagen by 62.6% during the third quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock worth $117,329,000 after acquiring an additional 991,325 shares in the last quarter. Point72 DIFC Ltd grew its stake in Qiagen by 10,610.4% in the third quarter. Point72 DIFC Ltd now owns 649,693 shares of the company’s stock valued at $29,606,000 after acquiring an additional 643,627 shares during the period. Finally, JPMorgan Chase & Co. increased its holdings in shares of Qiagen by 36.0% in the third quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock worth $73,096,000 after acquiring an additional 424,937 shares in the last quarter. Institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Morgan Stanley reiterated an “equal weight” rating and set a $48.00 price objective (down previously from $50.00) on shares of Qiagen in a report on Monday, January 6th. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Thursday, October 17th. Hsbc Global Res upgraded shares of Qiagen to a “hold” rating in a report on Thursday, October 17th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $54.00 target price (up from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Qiagen presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.50.

Qiagen Stock Performance

QGEN opened at $45.15 on Wednesday. The business’s 50-day simple moving average is $44.77 and its 200 day simple moving average is $44.37. Qiagen has a 52-week low of $39.03 and a 52-week high of $47.93. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.89 and a current ratio of 2.17. The firm has a market capitalization of $10.30 billion, a PE ratio of 115.78, a PEG ratio of 3.49 and a beta of 0.37.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.